



Akoya Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

January 11, 2021

MENLO PARK, Calif. — January 11, 2021— Akoya Biosciences, Inc., The Spatial Biology Company®, today announced that Brian McKelligon, the company's Chief Executive Officer, is scheduled to present at the J.P. Morgan 39th Annual Healthcare Conference on Wednesday, January 13, 2021. Mr. McKelligon will provide a company overview of Akoya and its spatial phenotyping solutions.

About Akoya Biosciences

Akoya Biosciences, The Spatial Biology Company®, offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and other immune system or neurological disorders. The CODEX® system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics™ platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials. For more information, please visit akoyabio.com.

Media Contact:

Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com